Dosing and uses of PABA, para aminobenzoic acid (aminobenzoate potassium)
Dosing Strengths & Forms
capsule
- 60mg
- 500mg
tablet
- 500mg
powder
- 2g
Supplement
12 g PO divided q4-6hr
Administration
Take with adequate liquid to avoid gastric upset
Pediatric dosage forms and strengths
Dosing Strengths & Forms
capsule
- 60mg
- 500mg
tablet
- 500mg
powder
- 2g
Supplement
1g/10 pounds of weight/day PO in divided doses
PABA, para aminobenzoic acid (aminobenzoate potassium) adverse (side) effects
Frequency not defined
Anorexia
Nausea
Fever
Hepatotoxicity
Rash
Warnings
Contraindications
Hypersensitivity
Concomitant sulfonamide antibiotics (effects may be nullified)
Cautions
Stop therapy if anorexia occurs and reinitiate therapy once appetite improves
Stop therapy if nausea occurs and reinitiate therapy once patient improves
Use wiht caution in diabetes mellitus, hypoglycemia, or renal disease
Pregnancy and lactation
Pregnancy category: Not studied
Lactation: Unknown if excreted in breast milk; use caution
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of PABA, para aminobenzoic acid (aminobenzoate potassium)
Mechanism of action
Related to B vitamins that may have antifibrotic effects by increasing oxygen uptake at tissues leveL
